Nuevolution operates the Chemetics® platform, which uses DNA labeling of small-molecule libraries to enable screening of more than one billion compounds to identify hits and leads for pharmaceutical development. The company focuses on identifying small-molecule lead compounds against therapeutically important, high-value targets, including challenging protein–protein interactions. Since 2008 the technology has been applied against a broad range of partnered targets that have been difficult to address with conventional HTS and medicinal chemistry. Leadership includes CEO Alex Gouliaev and Chairman Stig Løkke Pedersen. The company intends to use the new funding to expand its lead-identification business. The article notes a recent capital injection but does not disclose operating metrics such as revenue or user counts.

Total raised

$14M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2012